,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ABCC4,"EST170205, MOAT-B, MOATB, MRP4",ENSG00000125257,ATP binding cassette subfamily C member 4,13,95019829-95301446,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA002476,Enhanced,,,,"Renal cancer:2.25e-10 (favourable), Endometrial cancer:9.89e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,prostate: 70.4,epididymis: 23.6,Group enriched,5.0,HEL: 277.0;HMC-1: 278.6
1,ADRA1A,"ADRA1C, ADRA1L1",ENSG00000120907,Adrenoceptor alpha 1A,8,26748150-26867273,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA029678, HPA029679",Approved,,,,,Tissue enhanced,Tissue enhanced,,adipose tissue: 22.6;liver: 31.6;prostate: 20.8,seminal vesicle: 19.1,Not detected,,
2,ADRA1D,"ADRA1, ADRA1A, ADRA1R",ENSG00000171873,Adrenoceptor alpha 1D,20,4220631-4249074,"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA038789,Uncertain,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 4.3;prostate: 4.5",seminal vesicle: 2.6,Cell line enhanced,,BJ: 6.7;CAPAN-2: 3.1;fHDF/TERT166: 3.7
3,ALDH1A3,"ALDH6, RALDH3",ENSG00000184254,Aldehyde dehydrogenase 1 family member A3,15,100877714-100916626,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA046271, HPA064749",Enhanced,,Enhanced,Nucleus<br>Cytosol,,Group enriched,Tissue enhanced,,prostate: 217.5,adipose tissue: 74.8,Cell line enhanced,,HaCaT: 383.6;HBEC3-KT: 772.3;U-2197: 565.6;U-87 MG: 467.6;WM-115: 498.3
4,ALOX15B,15-LOX-2,ENSG00000179593,"Arachidonate 15-lipoxygenase, type B",17,8039017-8049134,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA010562,Enhanced,,Supported,Plasma membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,breast: 145.0;prostate: 115.3,lung: 26.1,Group enriched,15.0,HHSteC: 6.5;HSkMC: 11.9;hTCEpi: 25.0
5,ANO7,"IPCA-5, NGEP, PCANAP5, PCANAP5L, TMEM16G",ENSG00000146205,Anoctamin 7,2,241188509-241225377,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035730,Uncertain,,,,,Tissue enriched,Tissue enhanced,,prostate: 100.6;stomach: 26.0,small intestine: 15.4,Cell line enhanced,,BEWO: 2.1;Hep G2: 1.5
6,APELA,"ELA, Ende, tdl",ENSG00000248329,Apelin receptor early endogenous ligand,4,164877004-164898965,Predicted secreted proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,prostate: 6.3,kidney: 2.1,Cell line enriched,5.0,NTERA-2: 39.7
7,ARG2,,ENSG00000081181,Arginase 2,14,67619798-67651720,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA000663, CAB009435",Enhanced,,Supported,Mitochondria,,Expressed in all,Tissue enhanced,,parathyroid gland: 94.0;prostate: 161.0;thyroid gland: 157.2,kidney: 63.4,Cell line enhanced,,HAP1: 54.8
8,ARHGAP6,rhoGAPX-1,ENSG00000047648,Rho GTPase activating protein 6,X,11137543-11665701,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036779, HPA064390",Enhanced,,,,Renal cancer:1.55e-8 (favourable),Tissue enhanced,Tissue enhanced,,prostate: 44.3;seminal vesicle: 43.3,thyroid gland: 42.4,Cell line enhanced,,ASC TERT1: 23.8;HEL: 32.1;HMC-1: 21.3;HSkMC: 24.5;K-562: 23.6
9,ARHGEF38,FLJ20184,ENSG00000236699,Rho guanine nucleotide exchange factor 38,4,105552620-105708093,Predicted intracellular proteins,Evidence at protein level,"HPA036510, HPA045484",Uncertain,,Approved,Nucleoplasm<br>Centrosome,,Tissue enhanced,Tissue enhanced,,breast: 10.0;prostate: 9.3,epididymis: 6.8,Group enriched,8.0,RPTEC TERT1: 11.0;SK-BR-3: 6.0;T-47d: 7.9
10,AZGP1,"ZA2G, ZAG",ENSG00000160862,"Alpha-2-glycoprotein 1, zinc-binding",7,99966720-99976157,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA012582, CAB016087, CAB032276",Enhanced,,,,"Renal cancer:1.53e-4 (favourable), Liver cancer:2.90e-4 (favourable)",Group enriched,Tissue enhanced,,breast: 1201.5;liver: 1272.1;prostate: 1490.2;salivary gland: 1423.5,kidney: 294.4,Cell line enhanced,,Hep G2: 33.7;RPMI-8226: 79.5;T-47d: 35.0
11,BEND4,"CCDC4, FLJ35632, FLJ43965",ENSG00000188848,BEN domain containing 4,4,42110938-42152878,Predicted intracellular proteins,Evidence at protein level,HPA036850,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,,Group enriched,Tissue enhanced,,prostate: 5.3;testis: 17.7,lymph node: 2.5,Cell line enhanced,,HAP1: 35.3;HEL: 19.3;MOLT-4: 10.7;U-698: 9.6
12,BMPR1B,"ALK6, CDw293",ENSG00000138696,Bone morphogenetic protein receptor type 1B,4,94757968-95158448,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Endometrial cancer:2.84e-4 (favourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 37.2;prostate: 37.0",seminal vesicle: 21.0,Cell line enhanced,,A549: 21.1;SH-SY5Y: 20.1
13,C1orf116,"FLJ36507, MGC2742, MGC4309, SARG",ENSG00000182795,Chromosome 1 open reading frame 116,1,207018521-207032756,Predicted intracellular proteins,Evidence at protein level,"HPA011888, HPA011889",Enhanced,,Supported,Plasma membrane<br>Cytosol,Renal cancer:1.01e-5 (favourable),Mixed,Tissue enhanced,,esophagus: 112.4;lung: 109.2;prostate: 82.0,stomach: 54.9,Group enriched,5.0,A-431: 50.3;CAPAN-2: 87.3;HaCaT: 108.7;HBEC3-KT: 85.0;hTCEpi: 44.4;hTERT-HME1: 26.3;RPTEC TERT1: 42.8
14,CACNG4,"MGC11138, MGC24983",ENSG00000075461,Calcium voltage-gated channel auxiliary subunit gamma 4,17,66964910-67033398,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA005803, HPA065370",Enhanced,,Approved,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 48.6;prostate: 20.3,lung: 9.2,Cell line enriched,7.0,SH-SY5Y: 436.5
15,CDC42EP5,"Borg3, CEP5",ENSG00000167617,CDC42 effector protein 5,19,54465026-54473264,Predicted intracellular proteins,Evidence at protein level,HPA043449,Approved,,,,"Renal cancer:2.79e-5 (unfavourable), Urothelial cancer:1.36e-4 (favourable)",Expressed in all,Tissue enhanced,,colon: 3.1;prostate: 2.4,adipose tissue: 0.9,Not detected,,
16,CDH26,VR20,ENSG00000124215,Cadherin 26,20,59958427-60034011,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA015722, HPA047578",Uncertain,,Approved,Plasma membrane<br>Microtubules,"Lung cancer:3.75e-4 (favourable), Cervical cancer:7.62e-4 (favourable)",Group enriched,Tissue enhanced,,prostate: 19.1,urinary bladder: 6.1,Cell line enriched,6.0,RT4: 42.4
17,CDH7,,ENSG00000081138,Cadherin 7,18,65750252-65890341,Predicted membrane proteins,Evidence at protein level,HPA061419,Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 2.8;prostate: 1.3,testis: 0.7,Cell line enhanced,,AF22: 15.0;Karpas-707: 4.0;RH-30: 7.0;U-87 MG: 3.3
18,CFAP69,"C7orf63, FAP69, FLJ21062",ENSG00000105792,Cilia and flagella associated protein 69,7,90245174-90311063,Predicted intracellular proteins,Evidence at protein level,HPA062883,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,prostate: 25.2,fallopian tube: 17.9,Mixed,,
19,CFC1,"CRYPTIC, HTX2",ENSG00000136698,"Cripto, FRL-1, cryptic family 1",2,130592168-130599575,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA041773,Uncertain,,,,,Tissue enriched,Tissue enhanced,,pancreas: 4.1;prostate: 10.4;stomach: 8.0,fallopian tube: 1.6,Group enriched,18.0,RPMI-8226: 13.6;SCLC-21H: 12.6
20,CHRNA1,CHRNA,ENSG00000138435,Cholinergic receptor nicotinic alpha 1 subunit,2,174747592-174787935,"Disease related genes, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071554,Enhanced,,Supported,Plasma membrane,,Tissue enhanced,Tissue enhanced,,prostate: 3.2;skeletal muscle: 7.2,colon: 1.5,Group enriched,23.0,LHCN-M2: 370.9;RH-30: 348.5
21,CLUL1,,ENSG00000079101,Clusterin like 1,18,596988-650334,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB025264, HPA075240",Supported,,Approved,Endoplasmic reticulum<br>Plasma membrane,,Mixed,Tissue enhanced,,prostate: 13.9,thyroid gland: 11.5,Cell line enhanced,,Hep G2: 23.4
22,CPA6,CPAH,ENSG00000165078,Carboxypeptidase A6,8,67422038-67746385,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,prostate: 4.9;rectum: 2.9,colon: 1.7,Cell line enhanced,,CACO-2: 2.9;EFO-21: 1.8;Hep G2: 3.6
23,CPAMD8,"K-CAP, KIAA1283, VIP",ENSG00000160111,"C3 and PZP like, alpha-2-macroglobulin domain containing 8",19,16892947-17026815,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA031327, HPA031328, HPA031330",Uncertain,,,,,Mixed,Tissue enhanced,,prostate: 25.1;seminal vesicle: 52.1,lung: 22.8,Group enriched,10.0,BEWO: 18.7;EFO-21: 11.7;T-47d: 32.2
24,CPNE4,"COPN4, CPN4",ENSG00000196353,Copine 4,3,131533555-132285410,Predicted intracellular proteins,Evidence at protein level,"HPA032036, HPA078300",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enhanced,,cerebral cortex: 12.1;prostate: 40.8,seminal vesicle: 5.8,Cell line enhanced,,A549: 5.6;AF22: 5.6
25,CRISPLD1,"Cocoacrisp, DKFZp762F133, LCRISP1",ENSG00000121005,Cysteine rich secretory protein LCCL domain containing 1,8,74984515-75034558,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA024725,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,prostate: 39.6,breast: 35.0,Group enriched,5.0,AF22: 132.6;SH-SY5Y: 76.5
26,CUX2,"CDP2, CUTL2, KIAA0293",ENSG00000111249,Cut like homeobox 2,12,111034024-111350554,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 12.2;liver: 9.6;prostate: 18.0,thyroid gland: 6.8,Cell line enhanced,,HBEC3-KT: 4.6;SCLC-21H: 7.5;SH-SY5Y: 14.5
27,CWH43,"CWH43-C, FLJ21511",ENSG00000109182,Cell wall biogenesis 43 C-terminal homolog,4,48986247-49062081,Predicted membrane proteins,Evidence at protein level,"HPA042814, HPA048140",Uncertain,,,,"Renal cancer:2.29e-11 (favourable), Endometrial cancer:1.32e-4 (favourable)",Tissue enhanced,Tissue enhanced,,prostate: 67.5,skin: 29.6,Not detected,,
28,DLK2,"EGFL9, MGC2487",ENSG00000171462,Delta like non-canonical Notch ligand 2,6,43450352-43456632,Predicted membrane proteins,Evidence at transcript level,"HPA061223, HPA068672",Uncertain,,Approved,Nucleus,,Mixed,Tissue enhanced,,prostate: 9.3;skin: 14.5,seminal vesicle: 7.5,Cell line enhanced,,HaCaT: 21.0;hTCEpi: 27.7
29,EPHA3,"ETK, ETK1, HEK, HEK4, TYRO4",ENSG00000044524,EPH receptor A3,3,89107524-89482134,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB010462,Approved,,Uncertain,Nucleoplasm<br>Golgi apparatus<br>Cytosol,Renal cancer:3.28e-7 (unfavourable),Mixed,Tissue enhanced,,prostate: 51.9,gallbladder: 29.8,Cell line enriched,7.0,AF22: 192.5
30,EVX1,,ENSG00000106038,Even-skipped homeobox 1,7,27242700-27250493,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA055132,,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,adrenal gland: 3.7;prostate: 4.5;seminal vesicle: 4.0,testis: 1.3,Cell line enriched,10.0,RT4: 11.7
31,EVX2,,ENSG00000174279,Even-skipped homeobox 2,2,176077472-176083913,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA041576,Uncertain,,,,,Not detected,Tissue enhanced,,prostate: 2.0;seminal vesicle: 2.2;testis: 2.7,"cervix, uterine: 1.1",Not detected,,
32,EYA1,BOR,ENSG00000104313,EYA transcriptional coactivator and phosphatase 1,8,71197433-71362232,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA028917,,,Supported,Nucleoplasm<br>Nuclear bodies,,Mixed,Tissue enhanced,,parathyroid gland: 81.7;prostate: 21.2,cerebral cortex: 10.7,Cell line enhanced,,AN3-CA: 28.1;RH-30: 23.1;SH-SY5Y: 57.2
33,FEV,Pet-1,ENSG00000163497,"FEV, ETS transcription factor",2,218981087-218985657,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA067679,,Supported,Supported,Nuclear speckles,Pancreatic cancer:4.85e-4 (favourable),Group enriched,Tissue enhanced,,adrenal gland: 2.1;duodenum: 2.9;prostate: 1.9;stomach: 2.4,small intestine: 1.6,Group enriched,6.0,HMC-1: 22.4;SH-SY5Y: 34.6
34,FOXA1,HNF3A,ENSG00000129514,Forkhead box A1,14,37589984-37596059,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB011595, HPA050505",Enhanced,,Supported,Nucleoplasm<br>Nucleoli fibrillar center,Urothelial cancer:1.00e-4 (favourable),Tissue enhanced,Tissue enhanced,,prostate: 146.0,breast: 36.3,Cell line enhanced,,MCF7: 98.8;PC-3: 81.2;RT4: 94.9;SK-BR-3: 88.5;T-47d: 157.4
35,GABRG3,,ENSG00000182256,Gamma-aminobutyric acid type A receptor gamma3 subunit,15,26971282-27541991,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054010,Supported,,,,,Tissue enhanced,Tissue enhanced,,prostate: 10.6;testis: 16.5,cerebral cortex: 4.2,Cell line enhanced,,K-562: 4.0;PC-3: 5.1;U-87 MG: 14.0
36,GATA2,NFE1B,ENSG00000179348,GATA binding protein 2,3,128479427-128493185,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA005633, CAB024847",Approved,,Supported,Nucleoplasm,"Urothelial cancer:5.22e-5 (favourable), Renal cancer:2.04e-4 (favourable)",Expressed in all,Tissue enhanced,,prostate: 62.7;seminal vesicle: 74.7,endometrium: 40.5,Cell line enhanced,,BEWO: 272.0;HEL: 324.7;HMC-1: 165.0;SH-SY5Y: 347.2
37,GCNT2,"bA360O19.2, bA421M1.1, CCAT, GCNT5, IGNT, II, NACGT1, NAGCT1, ULG3",ENSG00000111846,"Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)",6,10492223-10629368,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA026776,Approved,,Supported,Golgi apparatus,,Mixed,Tissue enhanced,,prostate: 55.7,breast: 13.9,Cell line enhanced,,CACO-2: 39.6;EFO-21: 67.0
38,GCSAML,"C1orf150, FLJ44728",ENSG00000169224,Germinal center associated signaling and motility like,1,247507058-247577690,Predicted intracellular proteins,Evidence at protein level,"HPA027507, HPA027510",Uncertain,,Approved,Cytosol,,Tissue enriched,Tissue enhanced,,prostate: 9.1;testis: 7.3,lung: 3.3,Group enriched,98.0,HEL: 133.3;HMC-1: 495.5
39,GDF15,"MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB",ENSG00000130513,Growth differentiation factor 15,19,18374731-18389176,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA011191, CAB062554, HPA070957",Enhanced,,Enhanced,Golgi apparatus,,Expressed in all,Tissue enhanced,,placenta: 122.1;prostate: 74.5,kidney: 41.6,Cell line enhanced,,BEWO: 401.5;HHSteC: 474.6
40,GJC3,"CX30.2, GJE1",ENSG00000176402,Gap junction protein gamma 3,7,99923269-99929620,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA015024,Uncertain,,,,,Group enriched,Tissue enhanced,,breast: 8.7;prostate: 5.3,testis: 2.7,Cell line enhanced,,SK-MEL-30: 1.8;U-2197: 1.7
41,GLB1L2,,ENSG00000149328,Galactosidase beta 1 like 2,11,134331874-134378341,Predicted secreted proteins,Evidence at protein level,"HPA054808, HPA059955",Uncertain,,Supported,Nucleus,,Mixed,Tissue enhanced,,parathyroid gland: 53.2;prostate: 56.1,fallopian tube: 41.3,Cell line enhanced,,CAPAN-2: 43.7;HaCaT: 46.4;SCLC-21H: 41.1
42,GLB1L3,FLJ90231,ENSG00000166105,Galactosidase beta 1 like 3,11,134274245-134319564,Predicted intracellular proteins,Evidence at protein level,HPA039916,Uncertain,,,,Lung cancer:1.97e-4 (favourable),Tissue enhanced,Tissue enhanced,,prostate: 14.5;seminal vesicle: 7.0,cerebral cortex: 4.0,Cell line enhanced,,HEK93: 5.2;NTERA-2: 3.5;PC-3: 4.3;SCLC-21H: 8.6
43,GNG4,,ENSG00000168243,G protein subunit gamma 4,1,235547687-235650754,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,cerebral cortex: 25.3;ovary: 18.4;prostate: 17.5,endometrium: 8.4,Cell line enhanced,,NTERA-2: 75.6;SCLC-21H: 93.5;SH-SY5Y: 118.5
44,HIST1H2AD,"H2A.3, H2A/g, H2AFG",ENSG00000196866,Histone cluster 1 H2A family member d,6,26198851-26199243,Predicted intracellular proteins,Evidence at protein level,HPA041189,Supported,,,,,Mixed,Tissue enhanced,,bone marrow: 2.2;prostate: 1.9,esophagus: 1.2,Cell line enhanced,,U-266/70: 15.6;U-266/84: 5.0
45,HIST1H2BC,"H2B.1, H2B/l, H2BFL",ENSG00000180596,Histone cluster 1 H2B family member c,6,26114873-26123926,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042205, HPA043013, HPA048671",Supported,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:1.75e-5 (unfavourable), Pancreatic cancer:9.01e-4 (unfavourable)",Expressed in all,Tissue enhanced,,prostate: 35.5,bone marrow: 16.6,Cell line enhanced,,SiHa: 80.4;U-2 OS: 53.7
46,HIST1H2BF,"H2B/g, H2BFG",ENSG00000277224,Histone cluster 1 H2B family member f,6,26199520-26200715,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042205, HPA043013, HPA048671",Supported,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,esophagus: 3.5;prostate: 2.6,breast: 2.2,Cell line enhanced,,U-266/70: 18.9;U-266/84: 13.1
47,HIST1H2BG,"H2B.1A, H2B/a, H2BFA",ENSG00000273802,Histone cluster 1 H2B family member g,6,26215159-26216692,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042205, HPA043013, HPA048671",Supported,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:1.70e-8 (unfavourable),Expressed in all,Tissue enhanced,,breast: 17.5;prostate: 11.3,bone marrow: 4.6,Cell line enhanced,,SiHa: 11.2;T-47d: 19.9;U-266/70: 15.0
48,HIST2H2AA3,"H2A.2, H2A/q, H2AFO, HIST2H2AA",ENSG00000203812,Histone cluster 2 H2A family member a3,1,149842188-149842736,Predicted intracellular proteins,Evidence at protein level,HPA041189,Supported,,,,,Tissue enhanced,Tissue enhanced,,bone marrow: 112.2;prostate: 125.6,spleen: 42.0,Cell line enhanced,,U-266/70: 350.1;U-266/84: 191.4
49,HOXA13,"HOX1, HOX1J",ENSG00000106031,Homeobox A13,7,27193503-27200106,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 34.0;placenta: 24.5;prostate: 36.2;seminal vesicle: 32.5",rectum: 13.0,Cell line enhanced,,HAP1: 27.6;HEK93: 34.0;RT4: 33.4
50,HOXB13,,ENSG00000159184,Homeobox B13,17,48724763-48729178,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB004438, HPA062852, HPA065019",Enhanced,,Enhanced,Nucleoplasm,,Tissue enriched,Tissue enhanced,,prostate: 115.1;rectum: 39.0,colon: 21.4,Cell line enriched,13.0,PC-3: 139.6
51,IRX4,,ENSG00000113430,Iroquois homeobox 4,5,1877413-1887236,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA064094,,,Uncertain,Nucleus<br>Vesicles,,Mixed,Tissue enhanced,,prostate: 5.8;skin: 6.9,esophagus: 1.4,Cell line enhanced,,BEWO: 43.3;HaCaT: 15.1;HBEC3-KT: 6.7
52,ITGA8,,ENSG00000077943,Integrin subunit alpha 8,10,15513949-15720125,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA003432,Approved,,,,,Mixed,Tissue enhanced,,prostate: 59.5,seminal vesicle: 40.5,Cell line enhanced,,HEK93: 7.4;HMC-1: 17.0;HSkMC: 6.1;U-266/84: 6.6
53,KCNAB1,"AKR6A3, hKvb3, hKvBeta3, KCNA1B, Kvb1.3",ENSG00000169282,Potassium voltage-gated channel subfamily A member regulatory beta subunit 1,3,156037701-156539138,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA044550,Approved,,,,,Tissue enhanced,Tissue enhanced,,prostate: 37.4;thyroid gland: 48.4,seminal vesicle: 26.6,Cell line enhanced,,hTEC/SVTERT24-B: 5.2
54,KCNH6,"erg2, HERG2, Kv11.2",ENSG00000173826,Potassium voltage-gated channel subfamily H member 6,17,63523334-63548977,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 6.1;prostate: 5.4;small intestine: 5.5,duodenum: 2.2,Group enriched,6.0,SCLC-21H: 4.0;SH-SY5Y: 1.4
55,LA16c-312E8.5,,ENSG00000284395,,16,1431035-1433397,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,prostate: 2.6;stomach: 1.4,duodenum: 0.7,Cell line enriched,54.0,SCLC-21H: 38.7
56,LMAN1L,"ERGIC-53L, ERGL",ENSG00000140506,"Lectin, mannose binding 1 like",15,74812716-74825758,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,prostate: 91.3;spleen: 31.7,heart muscle: 12.7,Not detected,,
57,LRRC24,LRRC14OS,ENSG00000254402,Leucine rich repeat containing 24,8,144522377-144527032,Predicted membrane proteins,Evidence at protein level,"HPA028171, HPA052250",Enhanced,,Approved,Vesicles,,Not detected,Tissue enhanced,,parathyroid gland: 3.6;prostate: 4.5,cerebral cortex: 3.1,Cell line enhanced,,SCLC-21H: 3.2;SH-SY5Y: 7.9
58,MESP1,"bHLHc5, MGC10676",ENSG00000166823,Mesoderm posterior bHLH transcription factor 1,15,89748661-89751310,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA069981,,,Supported,Nucleus<br>Nucleoli,,Group enriched,Tissue enhanced,,adipose tissue: 4.8;prostate: 4.8,cerebral cortex: 1.4,Cell line enhanced,,A-431: 3.1;HDLM-2: 2.9;HEK93: 2.7;PC-3: 5.2;SCLC-21H: 3.0
59,MKX,"C10orf48, IRXL1, MGC39616",ENSG00000150051,Mohawk homeobox,10,27672875-27746060,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA006927,Uncertain,,Approved,Nucleoplasm<br>Nuclear speckles,,Mixed,Tissue enhanced,,ovary: 13.6;prostate: 26.0,fallopian tube: 8.2,Cell line enhanced,,BJ: 43.3;BJ hTERT+: 23.7;BJ hTERT+ SV40 Large T+: 30.7;fHDF/TERT166: 114.3
60,NLGN4Y,KIAA0951,ENSG00000165246,"Neuroligin 4, Y-linked",Y,14522638-14845650,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA001651,Approved,,,,,Mixed,Tissue enhanced,,prostate: 11.4;seminal vesicle: 12.5,cerebral cortex: 7.5,Cell line enhanced,,BJ hTERT+: 28.5;fHDF/TERT166: 21.5;HDLM-2: 30.2;hTCEpi: 16.2;U-138 MG: 23.0
61,NLRP9,"CLR19.1, NALP9, NOD6, PAN12",ENSG00000185792,NLR family pyrin domain containing 9,19,55708432-55738402,Predicted intracellular proteins,Evidence at transcript level,HPA042623,Uncertain,,,,,Tissue enriched,Tissue enhanced,,prostate: 1.4,testis: 0.6,Not detected,,
62,NPPC,CNP,ENSG00000163273,Natriuretic peptide C,2,231921820-231926403,"Predicted secreted proteins, Transporters",Evidence at protein level,HPA035362,Uncertain,,,,,Mixed,Tissue enhanced,,prostate: 6.9,cerebral cortex: 3.0,Cell line enhanced,,HEK93: 7.7;NTERA-2: 3.9;SCLC-21H: 6.4;SK-MEL-30: 18.9
63,NXPH4,NPH4,ENSG00000182379,Neurexophilin 4,12,57216795-57226449,Predicted secreted proteins,Evidence at transcript level,,,,,,"Renal cancer:7.68e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable), Endometrial cancer:6.21e-4 (unfavourable), Glioma:8.20e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 8.3;prostate: 7.1;skin: 12.2,placenta: 3.8,Cell line enhanced,,AN3-CA: 71.1;RH-30: 60.3
64,OR51E1,"GPR136, GPR164, OR51E1P, OR52A3P",ENSG00000180785,Olfactory receptor family 51 subfamily E member 1,11,4643420-4655488,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,"CAB019995, HPA051439",Approved,,,,Renal cancer:1.23e-6 (unfavourable),Tissue enriched,Tissue enhanced,,adipose tissue: 6.4;placenta: 9.6;prostate: 9.0,"smooth muscle,urinary bladder: 1.7",Cell line enriched,96.0,SCLC-21H: 10.5
65,PCOTH,C1QTNF9B-AS1,ENSG00000205861,Pro-X-Gly collagen triple helix like repeat containing,13,23888889-23897263,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,prostate: 24.5;skin: 25.5;testis: 38.3,epididymis: 6.1,Cell line enhanced,,hTEC/SVTERT24-B: 11.5;LHCN-M2: 10.9
66,PDE11A,,ENSG00000128655,Phosphodiesterase 11A,2,177623252-178108339,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA034560,Approved,,,,,Tissue enhanced,Tissue enhanced,,parathyroid gland: 10.5;prostate: 8.8,testis: 6.4,Cell line enhanced,,fHDF/TERT166: 2.2;Hep G2: 2.0
67,PDE9A,,ENSG00000160191,Phosphodiesterase 9A,21,42653636-42775509,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA011380,Enhanced,,Approved,Nucleoplasm<br>Vesicles,,Expressed in all,Tissue enhanced,,prostate: 56.8,spleen: 25.5,Cell line enhanced,,AF22: 29.5;EFO-21: 28.2;NTERA-2: 41.2;SCLC-21H: 26.8
68,PGM5,PGMRP,ENSG00000154330,Phosphoglucomutase 5,9,68328308-68531061,Predicted intracellular proteins,Evidence at protein level,"CAB034397, HPA046329, HPA067102",Enhanced,,,,Renal cancer:1.83e-5 (favourable),Tissue enhanced,Tissue enhanced,,prostate: 283.6;seminal vesicle: 327.6,smooth muscle: 217.9,Cell line enhanced,,PC-3: 55.9;RH-30: 40.1;SK-BR-3: 38.8
69,PI15,P25TI,ENSG00000137558,Peptidase inhibitor 15,8,74824537-74855029,Predicted secreted proteins,Evidence at protein level,"HPA006593, HPA030057",Uncertain,,Approved,Vesicles<br>Cytosol,,Group enriched,Tissue enhanced,,appendix: 73.2;prostate: 50.5;smooth muscle: 67.8,endometrium: 33.0,Group enriched,9.0,AF22: 21.0;SH-SY5Y: 22.2;SK-MEL-30: 22.4;U-266/70: 5.5
70,PMEPA1,"STAG1, TMEPAI",ENSG00000124225,"Prostate transmembrane protein, androgen induced 1",20,57648392-57711536,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA072291,,,Supported,Vesicles,"Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)",Expressed in all,Tissue enhanced,,"cervix, uterine: 146.1;prostate: 179.6",endometrium: 60.3,Cell line enhanced,,SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9
71,POTEG,"A26C2, CT104.4, POTE-14, POTE14, POTE14alpha",ENSG00000187537,POTE ankyrin domain family member G,14,19402486-19434341,Predicted intracellular proteins,Evidence at transcript level,HPA042822,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,prostate: 3.5,testis: 0.7,Not detected,,
72,PRAC2,"C17orf93, HOXB-AS5, HOXB13-AS1, NCRNA00253",ENSG00000229637,Prostate cancer susceptibility candidate 2,17,48723168-48724758,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,prostate: 16.8;rectum: 10.1,colon: 4.5,Group enriched,5.0,PC-3: 44.6;REH: 17.6
73,PRDM8,KMT8D,ENSG00000152784,PR/SET domain 8,4,80183879-80204329,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA057253,,,Approved,Nuclear bodies,,Tissue enhanced,Tissue enhanced,,prostate: 40.8;seminal vesicle: 37.7,cerebral cortex: 23.2,Cell line enhanced,,LHCN-M2: 34.7;NB-4: 30.5;SCLC-21H: 116.7
74,PRIM2,PRIM2A,ENSG00000146143,Primase (DNA) subunit 2,6,57314805-57646849,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA046566,,,Supported,Nucleoplasm,"Renal cancer:7.34e-6 (unfavourable), Ovarian cancer:3.00e-5 (favourable), Liver cancer:3.44e-5 (unfavourable), Pancreatic cancer:5.25e-4 (unfavourable), Endometrial cancer:6.98e-4 (unfavourable)",Expressed in all,Tissue enhanced,,prostate: 51.6,testis: 11.5,Expressed in all,,
75,PRKG2,"cGKII, PRKGR2",ENSG00000138669,"Protein kinase, cGMP-dependent, type II",4,81087370-81215117,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007386, CAB018739",Approved,,,,,Tissue enhanced,Tissue enhanced,,prostate: 15.3;small intestine: 14.4,duodenum: 9.7,Cell line enhanced,,HEL: 18.8;SCLC-21H: 7.3
76,QRFP,"26RFa, P518",ENSG00000188710,Pyroglutamylated RFamide peptide,9,130892702-130896812,Predicted secreted proteins,Evidence at transcript level,HPA043377,Uncertain,,,,,Mixed,Tissue enhanced,,prostate: 1.3,esophagus: 1.2,Cell line enhanced,,U-138 MG: 3.5
77,RAB27B,,ENSG00000041353,"RAB27B, member RAS oncogene family",18,54717860-54895516,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017712, HPA019849",Enhanced,,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,Pancreatic cancer:2.13e-4 (unfavourable),Mixed,Tissue enhanced,,prostate: 31.7;stomach: 40.5,cerebral cortex: 24.3,Cell line enhanced,,HEL: 54.6;U-87 MG: 154.0
78,RAB3B,,ENSG00000169213,"RAB3B, member RAS oncogene family",1,51907956-51990764,Predicted intracellular proteins,Evidence at protein level,"HPA003159, CAB023293",Enhanced,,Approved,Cell Junctions,,Group enriched,Tissue enhanced,,cerebral cortex: 8.2;prostate: 17.8,adrenal gland: 4.0,Cell line enhanced,,BJ: 105.7;TIME: 79.3
79,RANBP3L,FLJ25422,ENSG00000164188,RAN binding protein 3 like,5,36248434-36302114,Predicted intracellular proteins,Evidence at protein level,"HPA037471, HPA037472, HPA061526",Approved,,Uncertain,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 31.0;kidney: 28.7;prostate: 23.0,breast: 10.0,Cell line enhanced,,ASC diff: 8.5;HSkMC: 1.8;T-47d: 2.0
80,RCAN3,DSCR1L2,ENSG00000117602,RCAN family member 3,1,24502351-24541040,Predicted intracellular proteins,Evidence at protein level,"HPA034533, HPA064289",Enhanced,,Approved,Nucleoli fibrillar center<br>Nuclear speckles,,Expressed in all,Tissue enhanced,,prostate: 54.8,lymph node: 22.9,Mixed,,
81,RPE65,"BCO3, LCA2, rd12, RP20",ENSG00000116745,"RPE65, retinoid isomerohydrolase",1,68428822-68449959,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 2.7;prostate: 3.0;seminal vesicle: 6.2,endometrium: 1.0,Group enriched,27.0,A-431: 3.0;PC-3: 5.3;U-2 OS: 1.4
82,SALL3,ZNF796,ENSG00000256463,Spalt like transcription factor 3,18,78980275-79002677,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA016656,Uncertain,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 4.1;prostate: 2.0,kidney: 0.9,Group enriched,29.0,HAP1: 4.8;HEK93: 2.5;NTERA-2: 9.5
83,SBSPON,"C8orf84, RPESP",ENSG00000164764,Somatomedin B and thrombospondin type 1 domain containing,8,73064540-73124088,Predicted secreted proteins,Evidence at protein level,"HPA029595, CAB034214, CAB034332",Uncertain,,Approved,Vesicles,"Breast cancer:7.18e-4 (favourable), Renal cancer:8.82e-4 (unfavourable)",Mixed,Tissue enhanced,,prostate: 23.8,urinary bladder: 16.2,Group enriched,6.0,BJ: 7.6;RPTEC TERT1: 12.1
84,SEC14L2,"C22orf6, KIAA1186, KIAA1658, SPF, TAP, TAP1",ENSG00000100003,SEC14 like lipid binding 2,22,30396857-30425317,Predicted intracellular proteins,Evidence at protein level,HPA064466,Approved,,Supported,Nucleus<br>Cytosol,"Head and neck cancer:7.63e-6 (unfavourable), Breast cancer:3.05e-4 (favourable)",Expressed in all,Tissue enhanced,,epididymis: 104.9;liver: 125.6;prostate: 83.0,breast: 57.3,Cell line enhanced,,HBEC3-KT: 61.6
85,SELE,"CD62E, ELAM, ELAM1, ESEL",ENSG00000007908,Selectin E,1,169722641-169764705,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB002143,Enhanced,,,,,Mixed,Tissue enhanced,,parathyroid gland: 45.2;prostate: 46.4,urinary bladder: 27.8,Cell line enriched,6.0,HUVEC TERT2: 1.0
86,SHROOM1,"APXL2, KIAA1960",ENSG00000164403,Shroom family member 1,5,132822141-132830898,Predicted intracellular proteins,Evidence at protein level,"HPA037690, HPA037691",Uncertain,,Approved,Vesicles,Renal cancer:5.72e-6 (unfavourable),Expressed in all,Tissue enhanced,,prostate: 54.5,seminal vesicle: 21.3,Mixed,,
87,SIM2,"bHLHe15, MGC119447, SIM",ENSG00000159263,Single-minded family bHLH transcription factor 2,21,36699133-36749917,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA029295,Approved,,Supported,Nucleoplasm<br>Nuclear bodies,"Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.88e-4 (favourable)",Tissue enhanced,Tissue enhanced,,esophagus: 22.8;kidney: 13.0;prostate: 10.3,stomach: 5.1,Cell line enhanced,,PC-3: 40.7;RPTEC TERT1: 41.3;RT4: 26.9
88,SLC15A2,PEPT2,ENSG00000163406,Solute carrier family 15 member 2,3,121894089-121944102,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,"Cervical cancer:2.37e-4 (favourable), Lung cancer:6.74e-4 (favourable), Endometrial cancer:6.96e-4 (favourable)",Mixed,Tissue enhanced,,"cervix, uterine: 78.5;prostate: 64.9",epididymis: 47.8,Mixed,,
89,SLC2A12,"GLUT12, GLUT8",ENSG00000146411,Solute carrier family 2 member 12,6,133988697-134052636,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA031593, HPA031594",Approved,,Enhanced,Plasma membrane<br>Cell Junctions,,Tissue enriched,Tissue enhanced,,prostate: 43.3,endometrium: 16.1,Cell line enhanced,,CAPAN-2: 8.0;HaCaT: 6.1;U-2 OS: 10.1
90,SLC35F4,"C14orf36, FLJ37712",ENSG00000151812,Solute carrier family 35 member F4,14,57563922-57982194,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA043853,Uncertain,,Approved,Nucleoli fibrillar center,,Not detected,Tissue enhanced,,prostate: 1.9;seminal vesicle: 4.9;testis: 1.8,thyroid gland: 1.1,Cell line enhanced,,RPMI-8226: 1.0;U-87 MG: 2.0
91,SLC7A3,"ATRC3, CAT-3, FLJ14541",ENSG00000165349,Solute carrier family 7 member 3,X,70925582-70931125,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA003629,Approved,,,,,Tissue enriched,Tissue enhanced,,endometrium: 7.8;prostate: 9.9;seminal vesicle: 7.5,smooth muscle: 4.1,Cell line enhanced,,HAP1: 66.1;NTERA-2: 130.6;REH: 25.9
92,SLCO5A1,"OATP-J, OATP5A1, OATPRP4, SLC21A15",ENSG00000137571,Solute carrier organic anion transporter family member 5A1,8,69667047-69835064,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA025062,Uncertain,,,,,Mixed,Tissue enhanced,,prostate: 3.6,skeletal muscle: 2.6,Cell line enhanced,,HAP1: 5.7;NTERA-2: 3.6;RPMI-8226: 2.5;SCLC-21H: 4.6
93,SPDEF,"bA375E1.3, PDEF",ENSG00000124664,SAM pointed domain containing ETS transcription factor,6,34537802-34556333,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA055707,,,Supported,Nucleus<br>Nucleoli,Endometrial cancer:9.26e-9 (favourable),Group enriched,Tissue enhanced,,prostate: 172.4,breast: 42.6,Cell line enhanced,,MCF7: 221.8;SK-BR-3: 144.8;T-47d: 145.8
94,SPON2,DIL1,ENSG00000159674,Spondin 2,4,1166932-1208962,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA040170, HPA066095",Uncertain,,Approved,Vesicles,"Endometrial cancer:2.03e-4 (favourable), Urothelial cancer:9.22e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,endometrium: 105.2;prostate: 113.0,"cervix, uterine: 53.6",Group enriched,6.0,HHSteC: 216.0;HSkMC: 330.1
95,STAC,STAC1,ENSG00000144681,SH3 and cysteine rich domain,3,36380344-36548007,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA035143,Uncertain,,Uncertain,Nucleoplasm<br>Plasma membrane,,Mixed,Tissue enhanced,,parathyroid gland: 23.4;prostate: 21.7,lung: 15.8,Cell line enhanced,,fHDF/TERT166: 34.6;HaCaT: 28.9;SH-SY5Y: 48.5;U-87 MG: 45.7
96,STEAP1,"PRSS24, STEAP",ENSG00000164647,STEAP family member 1,7,90154375-90164829,"Cancer-related genes, Predicted membrane proteins, Transporters",Evidence at protein level,HPA030985,Uncertain,,,,,Tissue enriched,Tissue enhanced,,prostate: 119.0,appendix: 40.6,Cell line enhanced,,CAPAN-2: 106.6;U-138 MG: 147.9
97,SYT7,"IPCA-7, MGC150517, PCANAP7, SYT-VII",ENSG00000011347,Synaptotagmin 7,11,61515313-61581148,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012869,Enhanced,,,,"Renal cancer:1.16e-4 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 108.7;prostate: 84.8,placenta: 26.6,Cell line enhanced,,hTERT-HME1: 68.9;RT4: 30.1;SCLC-21H: 34.3;SK-BR-3: 31.0;T-47d: 38.2
98,TBL1Y,TBL1,ENSG00000092377,"Transducin beta like 1, Y-linked",Y,6910686-7091683,Predicted intracellular proteins,Evidence at protein level,HPA060073,Uncertain,,,,,Tissue enriched,Tissue enhanced,,prostate: 2.6;thyroid gland: 1.4,testis: 0.5,Cell line enhanced,,BEWO: 1.5;NTERA-2: 1.3;RT4: 1.2;SCLC-21H: 1.1;U-698: 6.6
99,TGFB2,,ENSG00000092969,Transforming growth factor beta 2,1,218346235-218444619,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enhanced,,prostate: 30.4,placenta: 20.4,Cell line enhanced,,EFO-21: 58.6;U-2 OS: 64.1
100,TMEFF2,"CT120.2, HPP1, TENB2, TPEF, TR",ENSG00000144339,Transmembrane protein with EGF like and two follistatin like domains 2,2,191949043-192195709,Predicted membrane proteins,Evidence at protein level,HPA015587,Uncertain,,Uncertain,Microtubules<br>Cytokinetic bridge,,Tissue enriched,Tissue enhanced,,cerebral cortex: 41.0;prostate: 64.1,seminal vesicle: 19.6,Group enriched,6.0,AF22: 38.8;LHCN-M2: 94.7
101,TMPRSS2,PRSS10,ENSG00000184012,"Transmembrane protease, serine 2",21,41464551-41531116,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA034493, HPA035787",Enhanced,,Supported,Nucleoplasm<br>Cell Junctions,"Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable)",Tissue enriched,Tissue enhanced,,prostate: 489.3,stomach: 142.6,Cell line enhanced,,CACO-2: 21.8;RT4: 50.4;SK-BR-3: 9.5
102,TMSB15A,"TMSL8, TMSNB",ENSG00000158164,Thymosin beta 15a,X,102513676-102516784,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,prostate: 22.5,thyroid gland: 8.5,Cell line enhanced,,AF22: 507.9;NTERA-2: 133.4;RH-30: 226.1;SH-SY5Y: 141.1
103,TRPV6,"CaT1, ECAC2",ENSG00000165125,Transient receptor potential cation channel subfamily V member 6,7,142871203-142885762,"Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA062864,Approved,,,,,Tissue enriched,Tissue enhanced,,prostate: 37.4;salivary gland: 28.9,placenta: 16.7,Cell line enhanced,,HaCaT: 16.0;RT4: 26.0;SK-BR-3: 17.7;T-47d: 49.5
104,TXNDC16,KIAA1344,ENSG00000087301,Thioredoxin domain containing 16,14,52430590-52552522,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA002543,Approved,,Approved,Mitochondria,Renal cancer:6.79e-4 (favourable),Expressed in all,Tissue enhanced,,prostate: 43.0,seminal vesicle: 18.3,Cell line enhanced,,SCLC-21H: 34.2
105,UNC5D,"KIAA1777, Unc5h4",ENSG00000156687,Unc-5 netrin receptor D,8,35235457-35796550,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA042940,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.2;duodenum: 6.1;prostate: 8.3,"cervix, uterine: 3.4",Cell line enhanced,,HEK93: 2.7;NTERA-2: 9.6;SH-SY5Y: 3.5;U-251 MG: 2.5
106,USP9Y,DFFRY,ENSG00000114374,"Ubiquitin specific peptidase 9, Y-linked",Y,12701231-12860839,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA057687,,,Uncertain,Vesicles,,Tissue enhanced,Tissue enhanced,,prostate: 9.9,seminal vesicle: 6.9,Cell line enhanced,,RPTEC TERT1: 13.3
107,VSTM2A,"MGC33530, VSTM2",ENSG00000170419,V-set and transmembrane domain containing 2A,7,54542325-54571080,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA021404, HPA024134",Uncertain,,,,Renal cancer:5.34e-4 (favourable),Tissue enhanced,Tissue enhanced,,adrenal gland: 12.7;cerebral cortex: 40.8;prostate: 15.5,stomach: 4.8,Cell line enhanced,,Karpas-707: 1.3;SCLC-21H: 6.9;SH-SY5Y: 4.3
108,WNK4,PRKWNK4,ENSG00000126562,WNK lysine deficient protein kinase 4,17,42780678-42796936,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA016500,Approved,,,,,Mixed,Tissue enhanced,,kidney: 19.0;prostate: 15.4;rectum: 12.0,colon: 8.8,Cell line enhanced,,fHDF/TERT166: 26.2;K-562: 34.7;TIME: 29.5;WM-115: 23.9
109,WNT5B,,ENSG00000111186,Wnt family member 5B,12,1529891-1647243,Predicted secreted proteins,Evidence at protein level,HPA061991,,,Approved,Vesicles,,Expressed in all,Tissue enhanced,,prostate: 34.7,seminal vesicle: 27.9,Cell line enhanced,,BJ: 195.3;BJ hTERT+ SV40 Large T+: 154.0;BJ hTERT+ SV40 Large T+ RasG12V: 132.9;HBF TERT88: 139.5;hTEC/SVTERT24-B: 144.8;U-138 MG: 140.4
110,ZNF613,FLJ13590,ENSG00000176024,Zinc finger protein 613,19,51927147-51948759,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA026833,Uncertain,,Approved,Nucleoplasm<br>Vesicles,Urothelial cancer:1.92e-6 (favourable),Expressed in all,Tissue enhanced,,prostate: 32.4,placenta: 9.8,Mixed,,
111,ZNF816-ZNF321P,ZNF816-ZNF321,ENSG00000221874,ZNF816-ZNF321P readthrough,19,52928475-52962823,Predicted intracellular proteins,Evidence at transcript level,HPA051271,Uncertain,,Uncertain,Nucleoplasm,,Not detected,Tissue enhanced,,prostate: 2.7,rectum: 1.6,Cell line enriched,7.0,RT4: 7.2
